iOnctura announces FDA clearance of IND application for roginolisib, a first-in-class allosteric modulator of PI3Kδ
Roginolisib is in development for solid and hematologic malignancies…
Leucid Bio to Participate in Upcoming Healthcare Conferences
London, UK – 31 October 2023 – Leucid Bio ("Leucid" or the…
Futura Medical Granted Marketing Authorisation for Eroxon® in Mexico
Futura Medical plc (AIM: FUM), the pharmaceutical company developing…
Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board
Invizius Limited (“Invizius”), a biotechnology company developing…
Astraveus awarded €10.4 million grant by the French government as part of France 2030 investment plan
Significant endorsement by the French government programme…
Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:…
Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023
Oslo, 23 October 2023. Lytix Biopharma – Lytix Biopharma AS…
Futura Medical Launches Eroxon® in the United Arab Emirates
Futura Medical plc (AIM: FUM), the pharmaceutical company developing…
4SC provides Q3 highlights and financial forecast
Planegg-Martinsried, Germany, 19 October 2023 – 4SC AG (4SC…
New Research Highlights Potential of iOnctura Strategy Combining Autotaxin and TGF-Β Inhibitors In Cancer
Amsterdam, The Netherlands and Geneva, Switzerland, 19 October…
4SC receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL in the European Union
The European Medicines Agency (EMA) has granted Orphan Drug…
Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from ’SkatteFUNN’
Oslo, 17 October 2023. Lytix Biopharma – Lytix Biopharma AS…
AMSilk appoints Gudrun Vogtentanz as Chief Scientific Officer
Munich, 17 October, 2023: AMSilk GmbH (“AMSilk”), the world’s…
STORM Therapeutics Presented Novel Pre-Clinical Data on STC-15 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
STORM’s first-in-class investigational drug STC-15 is the first…
Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company on its Oral Delivery Platform
Strategic collaboration focussed on the development of an optimised…
SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease
SpliceBio is eligible to receive upfront, opt-in…
SOTIO Enters Licensing Agreement With Synaffix to Expand ADC Pipeline
Synaffix to provide access to proprietary Antibody-Drug Conjugate…
Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published
Oslo, 16 October 2023. Lytix Biopharma – Lytix Biopharma AS…
Biocomposites announces new territories approved to promote STIMULAN® as an antibiotic carrier in bone and soft tissue
Argentina and Taiwan added to list of approved territories
STIMULAN…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York